Top Indian Pharma Companies Exports to USA market | Export market

Описание: Top Indian Pharma Companies Exports to USA market | Export market #USApharma #Indiapharma

Gland Pharma 54 % Exhibits extremely high export revenue: near 89 % of its total income in FY 2024-25. Exports span 65+ countries. Gland Pharma leads with one of the highest export ratios among Indian pharma firms, with nearly 89 % of its revenue from exports.
Dr. Reddy’s 53 % North America (primarily U.S.) accounted for 47 % of its FY 2024 sales . Likely exports exceed that margin.
Aurobindo Pharma 48 % U.S. market alone was 48 % of its revenue in FY 2023-24 , with over 70 % derived internationally .
Zydus (Cadila) 44 % U.S. was 46 % of its FY 2024 revenue —aligned with your figure.
Aurobindo Pharma and Zydus are heavily reliant on the U.S. market, contributing nearly half of their total revenue.
Piramal Pharma 41 % No exact export % found; but it serves 100+ countries via CDMO/Healthcare divisions. Piramal Pharma lacks a specific figure, but its global contract manufacturing and CDMO operations make exports a key part of its business model.
Lupin 34 % North America contributed 37 % of revenue in FY 2024 —your figure is in close proximity. Lupin’s exports are similarly substantial, at around one-third of its total revenue.
Sun Pharma 32 % U.S. revenue stood at 32 % in FY 2024; overseas markets overall contributed ~73 % .
Cipla 30 % North America accounted for 30 % in FY 2024 revenue. Historical data shows exports made up ~51 % in earlier years.
Sun Pharma and Cipla also generate a significant chunk (~30 %) of their sales from North America, though both enjoy broader global reach.

Tags:
Pharma Awareness, Abhijit Dey ,pharma exports from india, pharma export business in india, medicine export import business, India exports to USA, trump tariffs india, Top Indian Pharma Companies Exports to USA market, donald trump, world news, us tariffs on india,latest news, top news, trump tariffs india impact, trump tariffs india news